Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
UBS
Federal Trade Commission
Harvard Business School
Chinese Patent Office
Cerilliant
Argus Health
Accenture
Dow

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR METHYLNALTREXONE BROMIDE

« Back to Dashboard

Clinical Trials for Methylnaltrexone Bromide

Trial ID Title Status Sponsor Phase Summary
NCT00401375 Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI). Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 To evaluate the safety and efficacy of MNTX in patients who have undergone segmental colectomy and to assess if the time between the end of surgery and the first bowel movement is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo regimen.
NCT00401375 Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI). Completed Valeant Pharmaceuticals International, Inc. Phase 3 To evaluate the safety and efficacy of MNTX in patients who have undergone segmental colectomy and to assess if the time between the end of surgery and the first bowel movement is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo regimen.
NCT00547586 Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain Completed Progenics Pharmaceuticals, Inc. Phase 2 The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel dysfunction (OIBD).
NCT00547586 Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain Completed Valeant Pharmaceuticals International, Inc. Phase 2 The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel dysfunction (OIBD).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Methylnaltrexone Bromide

Condition Name

Condition Name for Methylnaltrexone Bromide
Intervention Trials
Opioid-Induced Constipation 5
Constipation 3
Ticagrelor 1
Methylnaltrexone 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Methylnaltrexone Bromide
Intervention Trials
Constipation 8
Ileus 1
Intestinal Obstruction 1
Opioid-Related Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Methylnaltrexone Bromide

Trials by Country

Trials by Country for Methylnaltrexone Bromide
Location Trials
United States 49
Canada 9
Australia 4
Germany 3
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Methylnaltrexone Bromide
Location Trials
New York 4
North Carolina 4
Alabama 3
Texas 3
Ohio 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Methylnaltrexone Bromide

Clinical Trial Phase

Clinical Trial Phase for Methylnaltrexone Bromide
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 2 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Methylnaltrexone Bromide
Clinical Trial Phase Trials
Completed 10
Unknown status 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Methylnaltrexone Bromide

Sponsor Name

Sponsor Name for Methylnaltrexone Bromide
Sponsor Trials
Valeant Pharmaceuticals International, Inc. 9
Progenics Pharmaceuticals, Inc. 4
Wyeth is now a wholly owned subsidiary of Pfizer 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Methylnaltrexone Bromide
Sponsor Trials
Industry 15
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Fuji
Boehringer Ingelheim
Accenture
Cipla
US Department of Justice
Colorcon
Citi
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.